Allergic Bronchopulmonary Aspergillosis (ABPA) is a complex, progressive fungal allergic lung disease that represents a critical, often under-diagnosed, complication in patients with asthma or cystic fibrosis (CF). This column provides a deep dive into ABPA, covering its pathogenesis, clinical presentation, state-of-the-art imaging features, diagnostic criteria, and the latest treatment strategies, drawing upon a recent clinical case and contemporary literature to offer a world-class expert perspective.
Pathophysiology: The Allergic Immune Cascade
ABPA is fundamentally a hypersensitivity reaction to species of Aspergillus, most commonly A. fumigatus, which colonizes the airways without causing invasive infection. The fungus, inhaled as conidia, germinates and grows as hyphae within the bronchial mucus, providing a constant antigenic load.
The key to ABPA's pathology is a pronounced Type I (IgE-mediated) and Type III (immune-complex mediated) hypersensitivity reaction. The host's immune system, typically skewed toward a T-helper cell type 2 (Th2) response, mounts an aggressive allergic reaction characterized by:
IgE and IgG Release: High levels of total serum IgE and Aspergillus-specific IgE and IgG antibodies are characteristic.
Eosinophilic Inflammation: A massive accumulation of eosinophils occurs in the peripheral blood (peripheral blood eosinophilia) and, critically, in the bronchial lumen, leading to eosinophilic pneumonia and mucoid impaction.
Airway Damage: Immune complexes and inflammatory cells deposit in the bronchial walls, causing necrosis, chronic inflammation, and ultimately, permanent airway damage known as bronchiectasis. This chronic inflammatory state, if untreated, progresses to airway remodeling, pulmonary fibrosis, and significant loss of lung function. Proteases from the fungus and neutrophils further contribute to epithelial injury.
Epidemiology: Who is at Risk?
ABPA is almost exclusively observed in patients with pre-existing pulmonary conditions, primarily asthma and cystic fibrosis (CF).
Prevalence: The exact incidence is not fully known, but ABPA is reported to affect approximately 1-2% of adult asthmatics and a higher proportion, between 1% and 15%, of patients with CF.
Under-diagnosis: The disease is often under-diagnosed due to its non-specific symptoms and the lack of standardized diagnostic criteria, especially in developing nations where it may be misdiagnosed as pulmonary tuberculosis.
Demographics: There is no known preference for a specific gender, and the prevalence can vary depending on the patient population, geography, and the diagnostic criteria used.
Clinical Presentation: Mimicking Exacerbations
The clinical presentation of ABPA is often non-specific, frequently mimicking an exacerbation of the underlying asthma or CF, or a recurrent pulmonary infection that fails to respond to conventional antibiotics. Common features include:
Poorly Controlled Asthma: Worsening or uncontrolled asthma is a major red flag.
Chronic Productive Cough: Coughing that may produce dirty-green or brown, thick, and rubbery mucus plugs (mucoid plug expectoration).
Recurrent Pulmonary Infiltrates: New or non-resolving opacities on chest imaging, often due to atelectasis from bronchial obstruction.
Systemic Symptoms: Malaise, fever, and anorexia are common in severe disease.
Hemoptysis: Coughing up blood may also occur.
Imaging Features:
Imaging plays a critical role, with both chest radiography and High-Resolution Computed Tomography (HRCT) revealing characteristic findings.
Chest Radiography
The classical, although transient, finding is the Finger-in-Glove sign. This sign represents mucoid impaction in the dilated bronchi, appearing as homogeneous, tubular, or branching opacities that typically radiate from the hilum toward the periphery, often in the upper lobes.
High-Resolution CT (HRCT)
HRCT is significantly more sensitive than radiography. The most common and critical findings include:
Central Bronchiectasis: Abnormal, often cylindrical or saccular, dilation of the central and larger airways, while the peripheral airways remain relatively spared. This is the most common finding.
Mucoid Impaction (Bronchoceles): Airway filling by thick mucoid secretions, seen as tubular or branching opacities (the CT correlate of the Finger-in-Glove sign).
Hyperattenuating Mucus (HAM): A highly specific finding for ABPA, where the impacted mucus plugs exhibit a high CT attenuation value (denser than paraspinal muscle) on non-contrast CT. This finding is strongly suggestive of ABPA.
Pulmonary Opacities: Consolidation or atelectasis (segmental, subsegmental, or lobar) secondary to bronchial obstruction by mucus plugs is frequently observed.
Other Findings: May include centrilobular nodules, tree-in-bud opacities (indicating small airway disease), and mosaic attenuation.
Case-Specific Imaging
The provided non-contrast chest CT images demonstrate several key ABPA features:
Figure 1 (A, B, C): cification in the right lower lobe (RLL) and evidence of tubular opacities/mucoid impaction. There are also tree-in-bud opacities noted in the lingula and right middle lobe. (D): Axial non-contrast Chest CT, Bone Window. Highlights a region of hyperattenuating mucus (High Attenuation Mucus - HAM) within the RLL, which is highly suggestive of Allergic Bronchopulmonary Aspergillosis (ABPA).
Figure 2 (A): Coronal non-contrast Chest CT, Lung Window. Shows a large, tubular opacity or mucoid impaction in the RLL, often referred to as the "Finger-in-Glove" sign. (B): Coronal non-contrast Chest CT, Bone Window. Corroborates the findings, though less visually striking than the axial bone window for HAM.
Differential Diagnosis and Definitive Diagnosis
Differential Diagnosis
The imaging and clinical presentation of ABPA must be distinguished from other conditions that cause mucoid impaction and consolidation:
Endobronchial Malignancy or Lesion: Tumors can cause obstructive pneumonitis and mucoid impaction, necessitating bronchoscopy to rule out.
Pneumonia: Bacterial, viral, or fungal pneumonias (especially recurrent).
Bronchiectasis: Non-ABPA related forms (e.g., post-infectious).
Cystic Fibrosis (CF): ABPA often complicates CF, but CF itself causes bronchiectasis and mucoid impaction.
Congenital Bronchial Atresia: A less common cause of mucoid impaction (bronchocele).
Diagnosis
The diagnosis of ABPA is complex, relying on a constellation of clinical, serologic, and radiologic findings. Diagnostic criteria generally include:
Pre-existing condition: Asthma or Cystic Fibrosis.
Immunologic evidence: Elevated serum total IgE (> 1000 ng/mL or > 417 IU/mL) and elevated Aspergillus-specific IgE/IgG.
Skin Reactivity: Immediate (Type I) cutaneous hypersensitivity to Aspergillus fumigatus antigen.
Radiographic Findings: Current or previous pulmonary infiltrates/opacities and evidence of central bronchiectasis on HRCT.
Microbiology: Positive Aspergillus precipitins (IgG antibodies) in blood.
The current case's most likely diagnosis is Allergic Bronchopulmonary Aspergillosis, strongly suggested by the imaging findings of high-attenuation mucus and mucoid impaction in a patient with chronic respiratory symptoms. Bronchoscopic confirmation of Aspergillus further solidifies the diagnosis.
Treatment and Prognosis: Suppressing Inflammation and Fungal Load
Treatment
The cornerstones of ABPA treatment are dual-pronged: controlling the hyperactive immune response and reducing the fungal burden in the airways.
Systemic Corticosteroids: Immunosuppression with prolonged courses of oral glucocorticosteroids (e.g., Prednisone) is the primary treatment to suppress the inflammatory response and clear pulmonary infiltrates, preventing the progression to irreversible bronchiectasis and fibrosis.
Antifungal Agents: Oral azole antifungals (e.g., itraconazole, voriconazole) are used as steroid-sparing agents to reduce the fungal load, especially for recurrent disease or those requiring high-dose steroids.
Biologics: In severe or refractory cases, monoclonal antibodies like Omalizumab (anti-IgE) are increasingly used to block the IgE pathway, a major driver of the allergic response.
Prognosis
ABPA is a chronic and relapsing disease. Early diagnosis and appropriate treatment are crucial to prevent irreversible complications. While long-term remissions are possible, the disease often does not remit completely. Untreated or poorly managed ABPA can lead to:
Progressive Bronchiectasis: Leading to recurrent infections.
Pulmonary Fibrosis: Causing permanent, severe loss of lung function and respiratory insufficiency.
Chronic Obstructive Pulmonary Disease (COPD): Long-term decline in forced expiratory volume in 1 second ($\text{FEV}_1$).
The clinical course is monitored by measuring total serum IgE levels, which are generally expected to decrease with effective treatment.
Quiz
Question 1. A 67-year-old female presents with chronic cough and recurrent pneumonia. Non-contrast chest CT reveals tubular opacities (mucoid impaction) in the right lower lobe, notably exhibiting higher attenuation than the paraspinal skeletal muscle. Which of the following is the most likely pathological characteristic of the mucus plugs in this patient?
A. Predominantly neutrophilic infiltrate.
B. High content of calcified material.
C. Massive accumulation of eosinophils.
D. High-density hemorrhage from alveolar bleeding.
E. Low-density fluid from recent aspiration pneumonia.
Question 2. The presence of tubular, branching opacities radiating from the hilum, often seen on chest radiography in ABPA, is classically known as which sign?
A. Halo sign.
B. Atoll sign.
C. Golden S-sign.
D. Finger-in-glove sign.
E. Tram-track sign.
Question 3. In treating an acute exacerbation of Allergic Bronchopulmonary Aspergillosis (ABPA), which therapeutic agent is considered the cornerstone of therapy to suppress the inflammatory response and prevent progressive lung damage?
A. Azithromycin (Macrolide antibiotic).
B. Itraconazole (Oral azole antifungal).
C. Omalizumab (Anti-IgE monoclonal antibody).
D. Systemic Glucocorticosteroids.
E. Inhaled Beta-agonists.
Answer & Explanation
1. Answer: C. Massive accumulation of eosinophils. Explanation: The characteristic finding of Hyperattenuating Mucus (HAM) in ABPA is highly suggestive of the diagnosis. Histologically, ABPA is a luminal hypereosinophilic disease where the mucus plugs are largely composed of eosinophilic inflammatory cells and cellular debris. While calcification can occur, the primary content is an eosinophilic inflammatory response.
2. Answer: D. Finger-in-glove sign. Explanation: The Finger-in-glove sign describes the characteristic radiological appearance of mucoid impaction in dilated bronchi, which is the pathognomonic finding on chest radiography and CT in ABPA. The Halo sign and Atoll sign are associated with invasive pulmonary aspergillosis (IPA) and organizing pneumonia, respectively. The Golden S-sign indicates central airway obstruction, often due to a mass.
3. Answer: D. Systemic Glucocorticosteroids. Explanation: Immunosuppression with systemic corticosteroids is the core treatment for ABPA, aimed at controlling the severe hypersensitivity reaction and preventing the development of irreversible bronchiectasis and pulmonary fibrosis. While itraconazole is a critical steroid-sparing agent used to reduce fungal load, corticosteroids are the primary anti-inflammatory agent for acute exacerbations.
References
[1] R. Agarwal, A. Khan, M. Garg, A. N. Aggarwal, and D. Gupta, “Pictorial essay: Allergic bronchopulmonary aspergillosis,” Indian J. Radiol. Imaging, vol. 21, no. 4, pp. 242–252, 2011.
[2] T. Franquet, N. L. Müller, A. Giménez, P. Guembe, J. de la Torre, and S. Bagué, “Spectrum of pulmonary aspergillosis: Histologic, clinical, and radiologic findings,” Radiographics, vol. 21, no. 4, pp. 825–837, 2001.
[3] K. Patterson and M. E. Strek, “Allergic bronchopulmonary aspergillosis,” Proc. Am. Thorac. Soc., vol. 7, no. 3, pp. 237–244, 2010.
[4] S. Shah and P. P. Jain, “Finger in Glove Sign,” Int. J. Res. Rev., vol. 3, no. 6, pp. 67–68, 2016.
[5] R. Agarwal, “Allergic Bronchopulmonary Aspergillosis,” MDPI, vol. 2, no. 2, p. 17, 2018.
[6] J. L. De La Hoz, K. G. Baddley, and M. R. O'Leary, “Allergic bronchopulmonary aspergillosis (ABPA): A review of the diagnosis, treatment, and prognosis,” J. Asthma Allergy, vol. 15, pp. 111–123, 2022.
[7] V. Dhooria, P. N. Dhooria, and R. Agarwal, “Allergic bronchopulmonary mycosis – pathophysiology, histology, diagnosis, and treatment,” Clin. Transl. Allergy, vol. 8, no. 1, p. 28, 2018.
[8] D. R. Greenberger, “Allergic bronchopulmonary aspergillosis (ABPA),” J. Allergy Clin. Immunol., vol. 147, no. 2, pp. 466–472, 2021.
Comments
Post a Comment